Long-acting insulin analogs: A review of "real-world" effectiveness in patients with type 2 diabetes

Current Diabetes Reviews

Volumn 7, Issue 1, 2011, Pages 61-74

  Pollock, Richard F ^a   Erny Albrecht, Katrina M ^b   Kalsekar, Anupama ^c   Bruhn, David ^c   Valentine, William J ^a  

^a Ossian Health Economics and Communications GmbH   (Switzerland)

^b MedWriters   (Switzerland)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

HbA1c; Hypoglycemia; Insulin detemir; Insulin glargine; Real world studies; Weight gain

Indexed keywords

HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

BODY WEIGHT; CLINICAL PRACTICE; COCHRANE LIBRARY; EMBASE; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MEDICAL LITERATURE; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THERAPY EFFECT; WEIGHT GAIN;

EID: 79952754657     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339911794273892     Document Type: Review

References (62)

1. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care 2009; 32: 193-203.
2. Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract 2007; 57: 455-460.
3. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26 Suppl 3: S18-S24.
4. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin ther- apy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005; 28: 2673-2679.
5. Rathmann W, Haastert B, Icks A, Giani G. Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994-2004. Diabetes Care 2007; 30: 848-53.
6. National Institute for Health and Clinical Excellence. NICE implementation uptake report: insulin glargine for diabetes (type 1 and type 2).2009. Available from:http://www.nice.org.uk/media/B3/7C/IMPUptakeReportTA53CG66GlarginevFinal.pdf
7. Tran K, Banerjee S, Li H, et al. Long-acting insulin analogues for the treatment of diabetes mellitus: Meta-analyses of Clinical Outcomes-Update of CADTH Technology Report No. 92. Ottawa: Canadian Agency for Drugs and Technologies in Health. 2008.
8. Warren E, Weatherley-Jones E, Chilcott J, Beverley C. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 2004; 8: 1-57.
9. Baxter MA. The role of new basal insulin analogues in the initia- tion and optimisation of insulin therapy in type 2 diabetes. Acta Diabetol 2008; 45: 253-268.
10. Thisted H, Johnsen SP, Rungby J. An update on the long-acting insulin analogue glargine. Basic Clin Pharmacol Toxicol 2006; 99: 1-11.
11. Home PD, Ashwell SG. An overview of insulin glargine. Diabetes Metab Res Rev 2002; 18 Suppl 3:S57-S63.
12. HOE 901/2004 Study Investigators Group.Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients. Diabet Med 2003; 20: 545-551.
13. Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003; 138: 952-959.
14. Massi BM, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003; 35:189-196.
15. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
16. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schern-thaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-416.
17. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005; 28: 950-955.
18. Rosenstock J, Schwartz SL, Clark CM, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-636.
19. Hollander P, Cooper J, Bregnhoj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008; 30: 1976-1987.
20. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.
21. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006; 28: 1569-1581.
22. Raslova K, Bogoev M., Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004; 66: 193-201.
23. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7: 56-64.
24. Joshi SR, Kalra S, Badgandi M, Rao YS, Chawla M. Designer insulins regimens in clinical practice--pilot multicenter Indian study. J Assoc Physicians India 2005; 53: 775-779.
25. Kanazawa Y, Igarashi Y, Komiya K, et al. Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2). Endocr J 2007; 54: 975-983.
26. Lechleitner M, Roden M, Haehling E, Mueller M. Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus. Wien Klin Wochenschr 2005; 117: 593-598.
27. Schreiber SA, Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab 2007; 9: 31-38.
28. Schreiber SA, Ferlinz K, Haak T. The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice. Diabetes Technol Ther 2008; 10: 121-127.
29. Siegmund T, Weber S, Blankenfeld H, Oeffner A, Schumm-Draeger PM. Comparison of insulin glargine versus NPH insulin in people with Type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin. Exp Clin Endocrinol Diabetes 2007; 115: 349-353.
30. Tahrani AA, Digwood S, Lee C, Moulik P. Evaluation of glargine group-start sessions in patients with type 2 diabetes as a strategy to deliver the service. Int J Clin Pract 2007; 61: 329-335.
31. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007; 30: 1127-1142.
32. Belsey J, Krishnarajah G. Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphony-lurea: a meta-analysis. Diabetes Obes Metab 2008; 10 Suppl 1: 1-7.
33. Swinnen SG, Devries JH. Contact frequency determines outcome of basal insulin initiation trials in type 2 diabetes. Diabetologia 2009; 52(11): 2324-2327.
34. Luddeke HJ, Sreenan S, Aczel S, et al. PREDICTIVE - a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab 2007; 9: 428-434.
35. Dornhorst A, Luddeke HJ, Sreenan S, et al. Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract 2008; 62: 659-665.
36. Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke HJ. Insulin detemir improves glycaemic control with less hypogly-caemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007; 9: 418-427.
37. Sreenan S, Virkamaki A, Zhang K, Hansen JB. Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study. Int J Clin Pract 2008; 62: 1971-1980.
38. Yenigun M, Honka M. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study. Int J Clin Pract 2009; 63: 425-432.
39. Dornhorst A, Luddeke HJ, Honka M et al. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin 2008; 24: 369-376.
40. Hermansen K, Lund P, Clemmensen K et al. 3-Month Results from Denmark within the Globally Prospective and Observational Study to Evaluate Insulin Detemir Treatment in Type 1 and Type 2 Diabetes: The PREDICTIVE Study. Rev Diabet Stud 2007; 4: 89-97.
41. Dornhorst A, Luddeke HJ, Sreenan S et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract 2007; 61: 523-528.
42. Dornhorst A, Luddeke HJ, Koenen C et al. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypogly-caemia: 14-week follow-up data from PREDICTIVE. Diabetes Obes Metab 2008; 10: 75-81.
43. Poole CD, Tetlow AP, McEwan P, Holmes P, Currie CJ. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin 2007; 23: S41-S48.
44. Borah BJ, Darkow T, Bouchard J, Aagren M, Forma F, Alemayehu B. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes. Clin Ther 2009; 31: 623-631.
45. Ciardullo AV, Bacchelli M, Daghio MM, Carapezzi C. Effectiveness and safety of insulin glargine in the therapy of complicated or secondary diabetes: clinical audit. Acta Diabetol 2006; 43: 57-60.
46. Hammer H, Klinge A. Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice. Int J Clin Pract 2007; 61: 2009-2018.
47. Mayerson AB. Levemir early clinical experience case series. Endocrinol Metab Clin North Am 2007; 36 Suppl 1: 45-52.
48. Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ, McE-wan P. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis. Cardiovasc Diabetol 2009; 8: 9.
49. Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ, McE-wan P. Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study. Cardiovasc Diabetol 2009; 8: 3.
50. Stroup J, Kane MP, Busch RS, Bakst G, Hamilton RA. The utility of insulin glargine in the treatment of diabetes mellitus. Pharmacotherapy 2004; 24: 736-742.
51. Rhoads GG, Kosiborod M, Nesto RW et al. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine. Am J Cardiol 2009; 104: 910-916.
52. Fabunmi R, Nielsen LL, Quimbo R et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 2009; 25: 777-786.
53. Schoffski O, Breitscheidel L, Benter U et al. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study. J Med Econ 2008; 11: 695-712.
54. Sun P, Wang R, Jacober S. The effectiveness of insulin initiation regimens in patients with type 2 diabetes mellitus: a large national medical records review study comparing a basal insulin analogue to premixed insulin. Curr Med Res Opin 2007; 23: 3017-3023.
55. Bullano MF, Fisher MD, Grochulski WD, Menditto L, Willey VJ. Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products. Am J Health Syst Pharm 2006; 63: 2473-2482.
56. Bullano MF, Al-Zakwani IS, Fisher MD, Menditto L, Willey VJ. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin 2005; 21: 291-298.
57. Schreiber SA, Russmann A. The effects of insulin glargine treatment and an educational programme on glycaemic control in type 2 diabetes patients in clinical practice. Curr Med Res Opin 2006; 22: 335-341.
58. Fischer JS, McLaughlin T, Loza L, Beauchamp R, Schwartz S, Kipnes M. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study. Curr Med Res Opin 2004; 20: 1703-1710.
59. Currie CJ, Poole CD, Tetlow AP, Holmes P, McEwan P. The outcome of care in peiople with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin 2007; 23: S33-S39.
60. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials.N Engl J Med 2000; 342(25): 1878-1886.
61. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342(25): 1887-1892.
62. Sørensen HT, Lash TL, Rothman KJ. Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. Hepatology 2006; 44(5): 1075-1082.